ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Clinical trial NCT02319005 · COMPLETED

Trial details

NCT number: NCT02319005
Sponsor: Alnylam Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)Amyloidosis, Hereditary Amyloid Neuropathies, Familial Amyloid Neuropathies Amyloidosis, Hereditary, Transthyretin-Related Familial Transthyretin Cardiac Amyloidosis

Start date: 2014-12-01
Primary completion: 2017-03-30
Enrollment: 206

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.